Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.

British Journal of Haematology
Ceri BygraveMartin Kaiser

Abstract

Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. Relapse within 12 months of autologous stem cell transplant was associated with markedly worse median progression-free survival 2 (PFS2) of 18 months and overall survival (OS) of 26 months, compared to median PFS2 of 85 months and OS of 91 months for later relapsing patients despite equal access to and use of subsequent therapies, highlighting the urgent need for improved outcome prediction and early intervention strategies for myeloma patients.

References

Apr 6, 2017·The New England Journal of Medicine·Michel AttalUNKNOWN IFM 2009 Study
Oct 15, 2018·Magnetic Resonance Imaging Clinics of North America·Christina Messiou, Martin Kaiser
Oct 31, 2018·Blood·Vallari ShahUNKNOWN National Cancer Research Institute Haematology Clinical Studies Group

❮ Previous
Next ❯

Citations

Jul 28, 2020·British Journal of Haematology·Meral Beksac, Bipin N Savani
Dec 8, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Shaji K KumarRashmi Kumar
May 1, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gian Maria ZaccariaFrancesca Gay

❮ Previous
Next ❯

Related Concepts